ABBV Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of -0.15% compared to AbbVie's net margin of 23.56%. AbbVie's return on equity of 61.64% beat Gilead Sciences's return on equity of 2.5%.

AbbVie has a consensus price target of $210.93, signalling upside risk potential of 21.93%. On the other hand Gilead Sciences has an analysts' consensus of $112.74 which suggests that it could grow by 7.85%. Given that AbbVie has higher upside potential than Gilead Sciences, analysts believe AbbVie is more attractive than Gilead Sciences.

AbbVie has a beta of 0.554, which suggesting that the stock is 44.574% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.322, suggesting its less volatile than the S&P 500 by 67.831%.

AbbVie has a quarterly dividend of $1.64 per share corresponding to a yield of 3.69%. Gilead Sciences offers a yield of 2.97% to investors and pays a quarterly dividend of $0.79 per share. AbbVie pays 257.71% of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

AbbVie quarterly revenues are $15.1B, which are larger than Gilead Sciences quarterly revenues of $7.6B. AbbVie's net income of -$22M is lower than Gilead Sciences's net income of $1.8B. Notably, AbbVie's price-to-earnings ratio is 72.08x while Gilead Sciences's PE ratio is 282.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie is 5.44x versus 4.57x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -0.15% compared to AbbVie's net margin of 50.24%. AbbVie's return on equity of 61.64% beat Johnson & Johnson's return on equity of 19.98%.

AbbVie has a consensus price target of $210.93, signalling upside risk potential of 21.93%. On the other hand Johnson & Johnson has an analysts' consensus of $170.21 which suggests that it could grow by 10.59%. Given that AbbVie has higher upside potential than Johnson & Johnson, analysts believe AbbVie is more attractive than Johnson & Johnson.

AbbVie has a beta of 0.554, which suggesting that the stock is 44.574% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.490, suggesting its less volatile than the S&P 500 by 50.995%.

AbbVie has a quarterly dividend of $1.64 per share corresponding to a yield of 3.69%. Johnson & Johnson offers a yield of 3.22% to investors and pays a quarterly dividend of $1.24 per share. AbbVie pays 257.71% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but AbbVie's is not.

AbbVie quarterly revenues are $15.1B, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. AbbVie's net income of -$22M is lower than Johnson & Johnson's net income of $11B. Notably, AbbVie's price-to-earnings ratio is 72.08x while Johnson & Johnson's PE ratio is 17.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie is 5.44x versus 4.18x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -0.15% compared to AbbVie's net margin of 32.59%. AbbVie's return on equity of 61.64% beat Eli Lilly and's return on equity of 80.24%.

AbbVie has a consensus price target of $210.93, signalling upside risk potential of 21.93%. On the other hand Eli Lilly and has an analysts' consensus of $1,008.89 which suggests that it could grow by 37.28%. Given that Eli Lilly and has higher upside potential than AbbVie, analysts believe Eli Lilly and is more attractive than AbbVie.

AbbVie has a beta of 0.554, which suggesting that the stock is 44.574% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.093%.

AbbVie has a quarterly dividend of $1.64 per share corresponding to a yield of 3.69%. Eli Lilly and offers a yield of 0.74% to investors and pays a quarterly dividend of $1.50 per share. AbbVie pays 257.71% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but AbbVie's is not.

AbbVie quarterly revenues are $15.1B, which are larger than Eli Lilly and quarterly revenues of $13.5B. AbbVie's net income of -$22M is lower than Eli Lilly and's net income of $4.4B. Notably, AbbVie's price-to-earnings ratio is 72.08x while Eli Lilly and's PE ratio is 62.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie is 5.44x versus 14.75x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of -0.15% compared to AbbVie's net margin of -117.16%. AbbVie's return on equity of 61.64% beat Moderna's return on equity of -29.09%.

AbbVie has a consensus price target of $210.93, signalling upside risk potential of 21.93%. On the other hand Moderna has an analysts' consensus of $51.14 which suggests that it could grow by 103%. Given that Moderna has higher upside potential than AbbVie, analysts believe Moderna is more attractive than AbbVie.

AbbVie has a beta of 0.554, which suggesting that the stock is 44.574% less volatile than S&P 500. In comparison Moderna has a beta of 2.231, suggesting its more volatile than the S&P 500 by 123.128%.

AbbVie has a quarterly dividend of $1.64 per share corresponding to a yield of 3.69%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AbbVie pays 257.71% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

AbbVie quarterly revenues are $15.1B, which are larger than Moderna quarterly revenues of $956M. AbbVie's net income of -$22M is higher than Moderna's net income of -$1.1B. Notably, AbbVie's price-to-earnings ratio is 72.08x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie is 5.44x versus 3.06x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.